OMRI Insider Trading Activity and SEC Form 4 Filings
OMRI insider trading summary
No open-market insider purchases or sales of Omrix Biopharmaceuticals, Inc. (OMRI) have been reported on SEC Form 4 in the past 12 months.
Latest OMRI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 31, 2008 | Nissim Mashiach | President and COO | Buy | $29K (2,000 @ $14.50) |
| Mar 26, 2008 | Philippe Romagnoli | Director | Buy | $106K (7,800 @ $13.59) |
| Mar 26, 2008 | Kevin Rakin | Director | Buy | $7K (500 @ $13.64) |
| Mar 26, 2008 | Kevin Rakin | Director | Buy | $20K (1,500 @ $13.65) |
| Mar 20, 2008 | Philippe Romagnoli | Director | Buy | $99K (8,250 @ $12.02) |
| Mar 20, 2008 | Robert Taub | Chief Executive Officer | Buy | $320K (26,400 @ $12.10) |
| Mar 19, 2008 | Robert Taub | Chief Executive Officer | Buy | $660K (53,600 @ $12.31) |
| Mar 19, 2008 | Philippe Romagnoli | Director | Buy | $171K (13,940 @ $12.24) |
| Mar 18, 2008 | V. Marc Droppert | Executive Vice President | Buy | $50K (4,000 @ $12.48) |
| Jan 4, 2008 | Michael Burshtine | Insider | Sell | $1.1M (32,665 @ $34.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.